Search Prime Grants

2051522

Project Grant

Overview

Grant Description
Sbir Phase I: Genetically Engineered Dendritic Cell to Activate Sars-Cov-2 Spike Protein Specific-T Cell (Covid-19)
Awardee
Place of Performance
Murrieta, California 92562-7022 United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Analysis Notes
Amendment Since initial award the End Date has been extended from 03/31/22 to 12/31/22.
Neyroblastgx was awarded Project Grant 2051522 worth $255,997 from Directorate for Technology, Innovation and Partnerships in April 2021 with work to be completed primarily in Murrieta California United States. The grant has a duration of 1 year 8 months and was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.

SBIR Details

Research Type
SBIR Phase I
Title
SBIR Phase I: Genetically Engineered Dendritic Cell to Activate SARS-CoV-2 Spike Protein specific-T Cell (COVID-19)
Abstract
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a specific immunoprotective cell therapy using the SARS-CoV-2 spike protein (Sp) to boost immunity against COVID-19, especially with comorbidities. A durable competitive advantage reflects immune cell engineering with novel coronavirus Sp as a new technological advancement for stem cell-based immunotherapy (SCT) to treat viral diseases, diabetes, autoimmune disorders, or cancer. Use of SCT against SARS-CoV-2 or new virus strains will prevent COVID-19 and post-infection complications, reduce the chance of future pandemics, and strengthen the local and national economy. This Small Business Innovative Research (SBIR) Phase I project will develop a "DC-COV19" probe system to eradicate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which killed more than 400,000 people in the United States. Our long-term goal is to develop a potent COVID-19 T cell-based immunotherapy (vaccine-like) for high-risk populations to stop or reduce SARS-CoV-2 infections. The SARS-CoV-2 vaccines target neutralizing antibodies but only rely on the endogenous production of T cells. Major Gap: COVID-19 patients showed a significant reduction in the number and function of T cells and required robust vaccine or immunotherapeutic strategies to boost SARS-CoV-2-specific CD4+ and CD8+ T cells. NeyroblastGX LLC (NGL) proposes to develop a probe from dendritic cells (DCs) derived from established genetically engineered human embryonic stem cells (hESC) transfected with SARS-CoV-2 spike protein (Sp). This "DC-COV19" probe will be used to produce high numbers of functional SARS-CoV-2-specific CD4+ and CD8+ T cells ex vivo. Autologous immune T cells will be transferred into COVID-19 patients as a rapid and robust adaptive T cell-based immunotherapy. NGL works with world-class immunologists and clinicians to develop several Sp constructs engineered to transfect DCs to selectively activate SARS-CoV-2-specific CD4+ and CD8+ T cells to fight COVID-19. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
PT
Solicitation Number
None

Status
(Complete)

Last Modified 8/18/22

Period of Performance
4/1/21
Start Date
12/31/22
End Date
100% Complete

Funding Split
$256.0K
Federal Obligation
$0.0
Non-Federal Obligation
$256.0K
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to 2051522

Transaction History

Modifications to 2051522

Additional Detail

Award ID FAIN
2051522
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
490707 DIVISION OF INDUSTRIAL INNOVATION
Awardee UEI
D7H1LWMAP6J3
Awardee CAGE
8JSA3
Performance District
42
Senators
Dianne Feinstein
Alejandro Padilla
Representative
Robert Garcia
Modified: 8/18/22